Recent studies reported that tumor-infiltrating CD39+ Tregs in CRC patients expressed different markers such as OX-40, CTLA-4 and ICOS, implicating their high immunosuppressive abilities in inhibiting anti-tumor immune responses [25, 26]. This evidence concerns the gene CTLA4 and colorectal carcinoma.